FY2026 EPS Estimates for Zai Lab Boosted by Leerink Partnrs

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2026 EPS estimates for shares of Zai Lab in a research note issued to investors on Monday, June 30th. Leerink Partnrs analyst J. Chang now expects that the company will earn $0.33 per share for the year, up from their previous estimate of $0.29. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. The firm had revenue of $106.49 million during the quarter, compared to analysts' expectations of $118.40 million.

Several other analysts have also recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th. JPMorgan Chase & Co. increased their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, March 13th. Scotiabank initiated coverage on shares of Zai Lab in a research report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 target price for the company. Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Finally, Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the stock an "outperform" rating in a research note on Monday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $54.28.

Zai Lab Stock Up 2.3%

ZLAB stock traded up $0.82 during trading on Wednesday, reaching $36.31. The company's stock had a trading volume of 400,028 shares, compared to its average volume of 908,274. The company's fifty day moving average is $33.66 and its 200-day moving average is $31.25. The company has a market capitalization of $4.03 billion, a P/E ratio of -14.60 and a beta of 0.99. Zai Lab has a 1 year low of $16.01 and a 1 year high of $44.34.

Insider Transactions at Zai Lab

In related news, Director William Lis sold 13,814 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.67, for a total value of $492,745.38. Following the sale, the director owned 35,106 shares in the company, valued at approximately $1,252,231.02. The trade was a 28.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Frazor Titus Edmondson III sold 1,874 shares of Zai Lab stock in a transaction on Friday, April 4th. The stock was sold at an average price of $33.11, for a total transaction of $62,048.14. Following the completion of the transaction, the insider directly owned 30,375 shares of the company's stock, valued at $1,005,716.25. The trade was a 5.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 158,826 shares of company stock valued at $4,900,539 over the last quarter. 4.96% of the stock is owned by insiders.

Hedge Funds Weigh In On Zai Lab

Several large investors have recently modified their holdings of ZLAB. US Bancorp DE grew its holdings in Zai Lab by 1,671.9% during the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock valued at $154,000 after purchasing an additional 5,534 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Zai Lab in the fourth quarter worth approximately $1,032,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Zai Lab in the fourth quarter worth approximately $1,674,000. Daiwa Securities Group Inc. boosted its holdings in Zai Lab by 44.7% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,833 shares of the company's stock valued at $362,000 after acquiring an additional 4,276 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Zai Lab by 39.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 841,735 shares of the company's stock valued at $22,045,000 after acquiring an additional 237,582 shares during the last quarter. Institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.